Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	FPG #8: Alternative Treatments in Psychiatry FPG #7: Critical Care in Neurology	Free Medical Books

Ovarian Neoplasms

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 61 articles: HTML format Text format

Single Articles

January 2012
1. YOSHIHARA K , Tsunoda T, Shigemizu D, Fujiwara H, et al
   High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by down-regulation of antigen presentation pathway.
   Clin Cancer Res. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   December 2011
2. LOCASALE JW , Zeskind B
   IL-6 and Ovarian Cancer--Letter.
   Clin Cancer Res. 2011.
   PubMed     Text format     Related articles   
   
   
   
   
3. BALKWILL FR , Coward J, Kulbe H, Milagre C, et al
   IL-6 and Ovarian Cancer--Response.
   Clin Cancer Res. 2011.
   PubMed     Text format     Related articles   
   
   
   
   
4. STEG AD , Bevis KS, Katre AA, Ziebarth A, et al
   Stem cell pathways contribute to clinical chemoresistance in ovarian cancer.
   Clin Cancer Res. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   November 2011
5. MOHEBTASH M , Tsang KY, Madan RA, Huen NY, et al
   A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer.
   Clin Cancer Res. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   October 2011
6. WITTINGER M , Vanhara P, El-Gazzar A, Brenner B, et al
   hVps37A Status Affects Prognosis and Cetuximab Sensitivity in Ovarian Cancer.
   Clin Cancer Res. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
7. RISCH HA , Berchuck A, Paul DP
   KRAS rs61764370 in Epithelial Ovarian Cancer-Response.
   Clin Cancer Res. 2011;17:6601.
   PubMed     Text format     Related articles   
   
   
   
   
8. WEIDHAAS JB , Slack FJ
   KRAS rs61764370 in Epithelial Ovarian Cancer-Letter.
   Clin Cancer Res. 2011;17:6600.
   PubMed     Text format     Related articles   
   
   
   
   September 2011
9. JIANG L , Siu MK, Wong OG, Tam KF, et al
   iASPP and Chemoresistance in Ovarian Cancers - Effects on Paclitaxel-Mediated Mitotic Catastrophe.
   Clin Cancer Res. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
10. MIYAMOTO S , Iwamoto R, Furuya A, Takahashi K, et al
    A Novel Anti-Human HB-EGF Monoclonal Antibody with Multiple Anti-Tumor Mechanisms Against Ovarian Cancer Cells.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2011
11. MARCHION DC , Cottrill HM, Xiong Y, Chen N, et al
    BAD phosphorylation determines ovarian cancer chemo-sensitivity and patient survival.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2011
12. COWARD J , Kulbe H, Chakravarty P, Leader DA, et al
    Interleukin-6 as a therapeutic target in human ovarian cancer.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
13. STEG AD , Katre AA, Goodman BW, Han HD, et al
    Targeting the Notch Ligand Jagged1 in Both Tumor Cells and Stroma in Ovarian Cancer.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    June 2011
14. HUANG RS , Johnatty SE, Gamazon ER, Im HK, et al
    Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2011
15. MABUCHI S , Hisamatsu T, Kawase C, Hayashi M, et al
    The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
16. ITAMOCHI H , Oishi T, Shimada M, Sato S, et al
    Inhibiting the mTOR pathway synergistically enhances cytotoxicity in ovarian cancer cells induced by etoposide through up-regulation of c-Jun.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
17. FARATIAN D , Zweemer A, Nagumo Y, Sims AH, et al
    Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
18. ZILLHARDT M , Park SM, Romero IL, Sawada K, et al
    Foretinib (GSK1363089), an orally available multi-kinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    April 2011
19. MORENO-SMITH M , Lu C, Shahzad MM, Armaiz-Pena GN, et al
    Dopamine blocks stress mediated ovarian carcinoma growth.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
20. VIVAS-MEJIA PE , Rodriguez-Aguayo C, Han HD, Shahzad MM, et al
    Silencing Survivin Splice Variant 2B Leads to Antitumor Activity in Taxane-Resistant Ovarian Cancer.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
21. DAI W , Teodoridis J, Zeller C, Graham JS, et al
    Systematic CpG Islands Methylation Profiling of Genes in the Wnt Pathway in Epithelial Ovarian Cancer Identifies Biomarkers of Progression-Free Survival.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2011
22. CHAKRAVARTY D , Saha Roy S, Challa R, Dandamudi R, et al
    Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
23. TAN DS , Iravani M, McCluggage WG, Lambros MB, et al
    Genomic Analysis Reveals the Molecular Heterogeneity of Ovarian Clear Cell Carcinomas.
    Clin Cancer Res. 2011;17:1521-1534.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
24. PHAROAH PD , Palmieri RT, Ramus SJ, Gayther SA, et al
    The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
25. SANTISKULVONG C , Konecny GE, Fekete M, Chen KY, et al
    Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2011
26. ANGLESIO MS , George J, Kulbe H, Friedlander ML, et al
    IL6-STAT3-HIF SIGNALLING AND THERAPEUTIC RESPONSE TO THE ANGIOGENESIS INHIBITOR, SUNITINIB, IN OVARIAN CLEAR CELL CANCER.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
27. YANG G , Xiao X, Rosen D, Cheng X, et al
    The Biphasic Role of NF-{kappa}B in Tumor Progression and Chemoresistance of Ovarian Cancer.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
28. MORSE MA , Alvarez Secord A, Blackwell KL, Hobeika A, et al
    MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T cell responses against breast and ovarian cancer.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
29. KIM HS , Han HD, Armaiz-Pena GN, Stone RL, et al
    Functional roles of Src and Fgr in ovarian carcinoma.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
30. WOLOSZYNSKA-READ A , Zhang W, Yu J, Link PA, et al
    Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with BORIS/CTCF expression ratio and advanced stage.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    January 2011
31. KONECNY GE , Winterhoff B, Kolarova T, Qi J, et al
    Expression of p16 and Retinoblastoma Determines Response to CDK 4/6 Inhibition in Ovarian Cancer.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
32. LIAO S , Liu J, Lin PC, Shi T, et al
    TGF-{beta} blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma model.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
33. ROSANO L , Cianfrocca R, Spinella F, Di Castro V, et al
    Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    December 2010
34. KENNY HA , Leonhardt P, Ladanyi A, Yamada SD, et al
    Targeting the Urokinase Plasminogen Activator Receptor Inhibits Ovarian Cancer Metastasis.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
35. GAO Z , Xu X, McClane B, Zeng Q, et al
    C-Terminus of Clostridium perfringens Enterotoxin Downregulates CLDN4 and Sensitizes Ovarian Cancer Cells to Taxol and Carboplatin.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    November 2010
36. YANG SW , Cody JJ, Rivera AA, Waehler R, et al
    Conditionally-Replicating Adenovirus Expressing TIMP2 for Ovarian Cancer Therapy.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
37. KORTMANN UK , McAlpine JN, Xue H, Guan J, et al
    Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
38. KELLY RJ , Draper D, Chen CC, Robey RW, et al
    A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist, Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
39. CHAMBERS SK , Clouser MC, Baker AF, Roe DJ, et al
    Overexpression of Tumor Vascular Endothelial Growth Factor A May Portend an Increased Likelihood of Progression in a Phase II Trial of Bevacizumab and Erlotinib in Resistant Ovarian Cancer.
    Clin Cancer Res. 2010;16:5320-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2010
40. SLUPSKY CM , Steed H, Wells T, Dabbs K, et al
    Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2010
41. KONNER J , Bell-McGuinn K, Sabbatini PJ, Hensley ML, et al
    Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor Alpha, in Epithelial Ovarian Cancer: A Phase I Study.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
42. MILLER S , Roussi P, Daly MB, Scarpato J, et al
    New Strategies in Ovarian Cancer: Uptake and experience of women at high risk of ovarian cancer who are considering risk-reducing salpingo-oophorectomy.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2010
43. LEDERMANN JA , Gabra H, Jayson GC, Spanswick VJ, et al
    Inhibition of carboplatin-induced DNA interstrand crosslink repair by gemcitabine in patients receiving these drugs for 'platinum-resistant' ovarian cancer.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
44. CERECER-GIL NY , Figuera LE, Llamas FJ, Lara M, et al
    Mutation of SDHB is a cause of hypoxia-related high-altitude paraganglioma.
    Clin Cancer Res. 2010;16:4148-54.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
45. GUO Y , Nemeth JA, O'Brien C, Susa M, et al
    Effects of Siltuximab on the IL-6 Induced Signaling Pathway in Ovarian Cancer.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
46. FU M , Maresh EL, Soslow RA, Alavi M, et al
    Epithelial membrane protein-2 is a novel therapeutic target in ovarian cancer.
    Clin Cancer Res. 2010;16:3954-63.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
47. HAN HD , Mangala LS, Lee JW, Shahzad MM, et al
    Targeted gene silencing using RGD-labeled chitosan nanoparticles.
    Clin Cancer Res. 2010;16:3910-22.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2010
48. CHEKMASOVA AA , Rao TD, Nikhamin Y, Park KJ, et al
    Successful Eradication of Established Peritoneal Ovarian Tumors in SCID-Beige Mice following Adoptive Transfer of T Cells Genetically Targeted to the MUC16 Antigen.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2010
49. YANG G , Rosen DG, Liu G, Yang F, et al
    CXCR2 Promotes Ovarian Cancer Growth through Dysregulated Cell Cycle, Diminished Apoptosis, and Enhanced Angiogenesis.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
50. CAREY MS , Agarwal R, Gilks B, Swenerton K, et al
    Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy.
    Clin Cancer Res. 2010;16:2852-60.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    April 2010
51. YANG G , Chang B, Yang F, Guo X, et al
    Aurora Kinase A Promotes Ovarian Tumorigenesis through Dysregulation of the Cell Cycle and Suppression of BRCA2.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
52. HUANG GS , Brouwer-Visser J, Ramirez MJ, Kim CH, et al
    Insulin-like Growth Factor 2 (IGF2) Expression Modulates Taxol Resistance and is a Candidate Biomarker for Reduced Disease-free Survival in Ovarian Cancer.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
53. WANG Y , Chan DW, Liu VW, Chiu P, et al
    Differential Functions of Growth Factor Receptor-Bound Protein 7 (GRB7) and Its Variant GRB7v in Ovarian Carcinogenesis.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
54. MUKHOPADHYAY A , Elattar A, Cerbinskaite A, Wilkinson SJ, et al
    Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2010
55. KUO KT , Mao TL, Chen X, Feng Y, et al
    DNA Copy Numbers Profiles in Affinity-Purified Ovarian Clear Cell Carcinoma.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
56. SANZ DJ , Acedo A, Infante M, Duran M, et al
    A High Proportion of DNA Variants of BRCA1 and BRCA2 Is Associated with Aberrant Splicing in Breast/Ovarian Cancer Patients.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2010
57. CORNEY DC , Hwang CI, Matoso A, Vogt M, et al
    Frequent Downregulation of miR-34 Family in Human Ovarian Cancers.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
58. KARYAMPUDI L , Formicola C, Erskine CL, Maurer MJ, et al
    A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102.
    Clin Cancer Res. 2010;16:825-34.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    January 2010
59. GOODE EL , Maurer MJ, Sellers TA, Phelan CM, et al
    Inherited Determinants of Ovarian Cancer Survival.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
60. ANNUNZIATA CM , Walker AJ, Minasian L, Yu M, et al
    Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
61. RASOOL N , Larochelle W, Zhong H, Ara G, et al
    Secretory Leukocyte Protease Inhibitor Antagonizes Paclitaxel in Ovarian Cancer Cells.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: